Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Trial Status:  Active
Results 1-25 of 1329 for your search:
Start Over
Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice
Phase: Phase IV
Type: Diagnostic
Status: Active
Age: 60 to 80
Sponsor: Other
Protocol IDs: PROLOG, NCT00675168
Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2612-3681, NCT00724581
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: simcere002, simcere0802, NCT00813332
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SIM090801, NCT01028729
Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: sim201002, NCT01211002
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RC08/29, NCT01320501
Maintenance Gemcitabine in the Chinese Advanced Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: SHPH-11ZL113, NCT01336192
Safety Evaluation of Dexmedetomidine for EBUS-TBNA
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 11021, NCT01381627
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 327/10, NCT01402089
Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
Phase: Phase IV
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PAN-001, NCT01658280
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV08, NCT01665417
Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COPPVATS vs 1.1, 2012-002409-23, NCT01741506
Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908010555, NCT01757158
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRST162.05, 2012-003544-68, NCT01848613
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IV-49, NCT01926171
Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Health services research, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Q-CROC-05, NCT02041468
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 5501068, NCT02088515
Validation of an Adjusted Dosing Algorithm of Carboplatin
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CARBMI, NCT02103244
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Phase: Phase IV
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-NSCL-005, NCT02151149
Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: yl-yxb08-lcsyfa-201302, NCT02195453
NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NEO09-100, NCT01394978
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.217, 2014-001077-14, NCT02208843
Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: APV-100, NCT02275702
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMPACT, 2012-000459-15, NCT02316327
Start Over